Plasma Proteome Profiling Reveals Inflammation Markers and Tafamidis Effects in V30M Transthyretin Polyneuropathy
Karina Nugroho(Scripps Research Institute), Jeffery W. Kelly(Scripps Research Institute), Jolene K. Diedrich(Scripps Research Institute), James J. Moresco(Southwestern Medical Center), Cecília Monteiro(Kaiser Permanente South San Francisco Medical Center), Evan T. Powers(Scripps Research Institute), Antônio F. M. Pinto(Salk Institute for Biological Studies), John R. Yates, Teresa Coelho(Universidade do Porto), Chung‐Yon Lin
Cited by 1
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
|New England Journal of Medicine|2013|961
ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificity
|Journal of Proteomics|2015|593